Citrate Promotes Excessive Lipid Biosynthesis and Senescence in Tumor Cells for Tumor Therapy
Source abstract
Abstract
Abstract Metabolic disorder is one of the hallmarks of cancers, and reprogramming of metabolism is becoming a novel strategy for cancer treatment. Citrate is a key metabolite and critical metabolic regulator linking glycolysis and lipid metabolism in cellular energy homeostasis. Here it is reported that citrate treatment (both sodium citrate and citric acid) significantly suppresses tumor cell proliferation and growth in various tumor types. Mechanistically, citrate promotes excessive lipid biosynthesis and induces disruption of lipid metabolism in tumor cells, resulting in tumor cell senescence and growth inhibition. Furthermore, ATM‐associated DNA damage response cooperates with MAPK and mTOR signaling pathways to control citrate‐induced tumor cell growth arrest and senescence. In vivo studies further demonstrate that citrate administration dramatically inhibits tumor growth and progression in a colon cancer xenograft model. Importantly, citrate administration combined with the conventional chemotherapy drugs exhibits synergistic antitumor effects in vivo in the colon cancer models. These results clearly indicate that citrate can reprogram lipid metabolism and cell fate in cancer cells, and targeting citrate can be a promising therapeutic strategy for tumor treatment.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer, Hypoxia, and Metabolism · Cancer, Lipids, and Metabolism · Peroxisome Proliferator-Activated Receptors
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Immunology Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province School of Medicine Jiangsu University Zhenjiang 212013 P. R. China
Division of Infectious Diseases Allergy & Immunology and Department of Internal Medicine Saint Louis University School of Medicine Saint Louis MO 63104 USA
Department of Molecular Microbiology & Immunology Saint Louis University School of Medicine Saint Louis MO 63104 USA
Funding
Melanoma Research Alliance
References (59)
Show source-provided references
1. 10.1016/j.ccr.2012.02.01410.1016/j.ccr.2012.02.014 ↗
2. 10.1038/nrc.2016.7710.1038/nrc.2016.77 ↗
3. 10.1038/oncsis.2015.4910.1038/oncsis.2015.49 ↗
4. 10.1038/nrclinonc.2016.6010.1038/nrclinonc.2016.60 ↗
5. 10.1158/0008-5472.CAN-11-012710.1158/0008-5472.CAN-11-0127 ↗
6. 10.1038/nrd350410.1038/nrd3504 ↗
7. 10.1158/2159-8290.CD-16-061510.1158/2159-8290.CD-16-0615 ↗
8. 10.1038/s41586-018-0729-310.1038/s41586-018-0729-3 ↗
9. 10.1038/s41586-019-1340-y10.1038/s41586-019-1340-y ↗
10. 10.1002/bies.08013710.1002/bies.080137 ↗
11. 10.1515/hsz-2013-027110.1515/hsz-2013-0271 ↗
12. 10.3389/fimmu.2018.0014110.3389/fimmu.2018.00141 ↗
13. 10.1016/j.bbcan.2011.10.00710.1016/j.bbcan.2011.10.007 ↗
14. 10.1016/j.drup.2016.09.00310.1016/j.drup.2016.09.003 ↗
15. 10.1371/journal.pone.006237510.1371/journal.pone.0062375 ↗
16. 10.1016/j.bbcan.2019.18833210.1016/j.bbcan.2019.188332 ↗
17. 10.3389/fcell.2020.60247610.3389/fcell.2020.602476 ↗
18. 10.1158/0008-5472.CAN-17-295910.1158/0008-5472.CAN-17-2959 ↗
19. 10.1038/s41598-017-04626-410.1038/s41598-017-04626-4 ↗
20. 10.1038/ng.276410.1038/ng.2764 ↗
21. Qian X. · Int. J. Clin. Exp. Med. · 2015 · 8 · 7855
22. 10.1371/journal.pone.012635710.1371/journal.pone.0126357 ↗
23. 10.1186/s12967-019-1884-510.1186/s12967-019-1884-5 ↗
24. 10.1002/pros.299018010410.1002/pros.2990180104 ↗
25. Zhang X. · Anticancer Res. · 2009 · 29 · 1249
26. Lu Y. · Anticancer Res. · 2011 · 31 · 797
27. 10.1016/j.tcb.2018.02.00110.1016/j.tcb.2018.02.001 ↗
28. Liu X. · J. Immunol. · 2018 · 200
29. 10.15252/emmm.20140391810.15252/emmm.201403918 ↗
30. 10.1242/jcs.113.20.361310.1242/jcs.113.20.3613 ↗
31. 10.1182/blood-2012-03-41604010.1182/blood-2012-03-416040 ↗
32. 10.1016/j.cmet.2018.09.02010.1016/j.cmet.2018.09.020 ↗
33. 10.1038/s41467-017-02689-510.1038/s41467-017-02689-5 ↗
34. 10.4161/2162402X.2014.99439810.4161/2162402X.2014.994398 ↗
35. 10.1038/nrc244010.1038/nrc2440 ↗
36. 10.1242/dmm.01133810.1242/dmm.011338 ↗
37. 10.1038/s41580-018-0085-z10.1038/s41580-018-0085-z ↗
38. 10.1038/nprot.2013.05510.1038/nprot.2013.055 ↗
39. 10.1126/scitranslmed.aaz631410.1126/scitranslmed.aaz6314 ↗
40. 10.1016/j.bbalip.2014.10.00410.1016/j.bbalip.2014.10.004 ↗
41. 10.1161/ATVBAHA.119.31213610.1161/ATVBAHA.119.312136 ↗
42. 10.4049/jimmunol.120236910.4049/jimmunol.1202369 ↗
43. 10.1016/j.tibs.2014.04.00410.1016/j.tibs.2014.04.004 ↗
44. 10.1016/j.bbcan.2019.18833210.1016/j.bbcan.2019.188332 ↗
45. 10.2174/156652401666615112310485510.2174/1566524016666151123104855 ↗
46. 10.1158/0008-5472.CAN-18-189910.1158/0008-5472.CAN-18-1899 ↗
47. 10.1016/j.mehy.2009.03.01810.1016/j.mehy.2009.03.018 ↗
48. 10.1016/j.clinre.2010.12.01110.1016/j.clinre.2010.12.011 ↗
49. 10.1007/s00018-012-1166-310.1007/s00018-012-1166-3 ↗
50. 10.1186/1757-2215-6-7210.1186/1757-2215-6-72 ↗
51. 10.1038/nrc305710.1038/nrc3057 ↗
52. 10.1186/s12943-018-0824-y10.1186/s12943-018-0824-y ↗
53. 10.1038/s41419-017-0223-010.1038/s41419-017-0223-0 ↗
54. 10.18632/oncotarget.2401510.18632/oncotarget.24015 ↗
55. 10.18632/oncotarget.349310.18632/oncotarget.3493 ↗
56. 10.1073/pnas.122240411010.1073/pnas.1222404110 ↗
57. 10.1038/cdd.2012.3410.1038/cdd.2012.34 ↗
58. 10.1038/sj.bjc.660451010.1038/sj.bjc.6604510 ↗
59. 10.1038/s41598-018-27521-y10.1038/s41598-018-27521-y ↗